Statins for Cardiac and Vascular Protection During and After Cancer Therapy.

ABSTRACT:

Purpose of review

Although cancer treatments have increased overall survival rates, the cardiovascular consequences of cancer therapy place patients at an increased risk of adverse outcomes. This manuscript presents data accumulated to date regarding cardiovascular outcomes relating to the administration of 3-hydroxy-3-methylglutarylcoenzyme-A reductase inhibitor (or statin) therapy in individuals receiving potentially cardiotoxic cancer treatments.

Recent findings

Retrospective observational studies in humans and randomized controlled trials in animals suggest that statins may reduce cancer-specific and all-cause mortality. Further, statins may attenuate cancer therapy-induced declines in left ventricular ejection fraction (LVEF) and increases in blood pressure. Observation

SUBMITTER: Heiston EM 

PROVIDER: S-EPMC9922479 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature